[redacted]

```
=>
=> s l1 sss full
FULL SEARCH INITIATED 09:25:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      434 TO ITERATE

100.0% PROCESSED      434 ITERATIONS                                62 ANSWERS
SEARCH TIME: 00.00.01

L3           62 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     185.15     185.36

FILE 'CAPLUS' ENTERED AT 09:25:21 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007  (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4           93 L3

=> s l4 and diabetes
        125334 DIABETES
L5           73 L4 AND DIABETES

=> s l5 and obesity and high blood pressure
         42852 OBESITY
       4050662 HIGH
       1307090 BLOOD
       1247826 PRESSURE
          2402 HIGH BLOOD PRESSURE
                 (HIGH(W)BLOOD(W)PRESSURE)
L6            4 L5 AND OBESITY AND HIGH BLOOD PRESSURE

=> d l6 ibib abs hitstr 1-4
```

[redacted]

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:298857 CAPLUS
DOCUMENT NUMBER: 144:338150
TITLE: Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
INVENTOR(S): Ferlita, Russell R.; Wenslow, Robert M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006033848	A1	20060330	WO 2005-US32079	20050909

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-610019P P 20040915

AB The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine as well as a process for its preparation, pharmaceutical compns. containing this novel form, and methods of use of the novel form and pharmaceutical compns. for the treatment of diabetes, obesity, and high blood pressure.

IT 654671-78-0P
RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor)

RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

[redacted]

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:300188 CAPLUS
DOCUMENT NUMBER: 142:360851
TITLE: Novel crystalline form of a phosphate salt of a dipeptidyl peptidase-IV inhibitor
INVENTOR(S): Chen, Alex M.; Wenslow, Robert M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030127	A2	20050407	WO 2004-US30434	20040917
WO 2005030127	A3	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667524	A2	20060614	EP 2004-784324	20040917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007021430	A1	20070125	US 2006-570409	20060303
PRIORITY APPLN. INFO.:			US 2003-505118P P	20030923
			WO 2004-US30434 W	20040917

AB The present invention relates to a novel crystalline anhydrate polymorph of the dihydrogen phosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine as well as a process for their preparation, pharmaceutical compns. containing this form, and methods of use of the form for the treatment of diabetes, obesity, and high blood pressure.

IT 654671-77-9P 654671-78-0P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline form of phosphate salt of dipeptidyl peptidase-IV inhibitor)
RN 654671-77-9 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 486460-32-6P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(crystalline form of phosphate salt of dipeptidyl peptidase-IV inhibitor)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



[redacted]

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:216618 CAPLUS
DOCUMENT NUMBER: 142:303604
TITLE: Novel crystal forms of a dihydrogen phosphate salt of a trizolopyrazine dipeptidyl peptidase IV inhibitor
INVENTOR(S): Wenslow, Robert M.; Armstrong, Joseph D., III; Chen, Alex M.; Cypes, Stephen; Ferlita, Russell R.; Hansen, Karl; Lindemann, Christopher M.; Spartalis, Evangelia
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005020920	A2	20050310	WO 2004-US27983		20040827
WO 2005020920	A3	20050428			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004268024	A1	20050310	AU 2004-268024		20040827
CA 2536251	A1	20050310	CA 2004-2536251		20040827
EP 1662876	A2	20060607	EP 2004-782460		20040827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1845674	A	20061011	CN 2004-80025043		20040827
JP 2007504230	T	20070301	JP 2006-525371		20040827
US 2006287528	A1	20061221	US 2006-569566		20060227
PRIORITY APPLN. INFO.:			US 2003-499629P	P	20030902
			WO 2004-US27983	W	20040827

OTHER SOURCE(S): CASREACT 142:303604
GI



I

AB The present invention relates to crystalline anhydrate polymorphs of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine dihydrogen phosphate salt (I) as well as a process for their preparation,

[redacted]

pharmaceutical compns. containing these novel forms, and methods of use of the novel forms and pharmaceutical compns. for the treatment of diabetes, obesity, and high blood pressure.

IT 486460-32-6P 654671-78-0P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal forms of a trizolopyrazine dihydrogen phosphate salt dipeptidyl peptidase IV inhibitor)

RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 847445-75-4 847445-76-5 847445-77-6
847445-78-7 847445-79-8 847445-80-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal forms of a trizolopyrazine dihydrogen phosphate salt dipeptidyl peptidase IV inhibitor)
RN 847445-75-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with 2-propanone (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 67-64-1
CMF C3 H6 O



[redacted]

RN 847445-76-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with acetonitrile (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 75-05-8
CMF C2 H3 N



RN 847445-77-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with methanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 67-56-1
CMF C H4 O



RN 847445-78-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with ethanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



[redacted]

CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 64-17-5
CMF C2 H6 O



RN 847445-79-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with 1-propanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



[redacted]

CM 3

CRN 71-23-8
CMF C3 H8 O



RN 847445-80-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with 2-propanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 67-63-0
CMF C3 H8 O



[redacted]

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:29336 CAPLUS
DOCUMENT NUMBER: 142:114455
TITLE: Preparation of phosphoric acid salt of a β-amino acid amide dipeptidyl peptidase-IV inhibitor and its monohydrate
INVENTOR(S): Cypes, Stephen Howard; Chen, Alex Minhua; Ferlita, Russell R.; Hansen, Karl; Lee, Ivan; Vydra, Vicky K.; Wenslow, Robert M., Jr.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003135	A1	20050113	WO 2004-US19683	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004253889	A1	20050113	AU 2004-253889	20040618
CA 2529400	A1	20050113	CA 2004-2529400	20040618
EP 1654263	A1	20060510	EP 2004-755691	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006516268	T	20060629	JP 2005-518292	20040618
BR 2004011726	A	20060808	BR 2004-11726	20040618
CN 1832949	A	20060913	CN 2004-80017544	20040618
US 2005032804	A1	20050210	US 2004-874992	20040623
NO 2006000362	A	20060323	NO 2006-362	20060123
PRIORITY APPLN. INFO.:			US 2003-482161P P	20030624
			WO 2004-US19683 W	20040618

GI



I



II



III

AB The invention is related to the preparation of dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine (I•H3PO4) which is a potent inhibitor of dipeptidyl peptidase-IV and therefore useful for the prevention and/or treatment of type 2 diabetes. The invention also relates to the preparation of hydrates, in particular a crystalline monohydrate of the dihydrogenphosphate salt I, its pharmaceutical compns., and methods of use for the treatment of diabetes, obesity, and high blood pressure. Thus, treating II•HCl (preparation given) with III (preparation given), followed by reaction with NH4OAc in MeOH, and hydrogenation gave amine (R)-I. Reaction of amine (R)-I with 85% aqueous H3PO4 and recrystn. from isopropanol/water gave (R)-I•H3PO4•H2O.

IT 654671-77-9P, (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine dihydrogen phosphate monohydrate
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(DPPIV inhibitor; preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)

RN 654671-77-9 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 486460-32-6P, (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 654671-78-0P 823817-57-8P 823817-58-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1)

[redacted]

(CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 823817-57-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 823817-56-7
CMF C16 H15 F6 N5 O



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 823817-58-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3S)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 823817-55-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 823817-56-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 823817-56-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 823817-55-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 823817-55-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3S)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

[redacted]

=> d his

(FILE 'HOME' ENTERED AT 09:22:32 ON 29 MAY 2007)

FILE 'REGISTRY' ENTERED AT 09:22:44 ON 29 MAY 2007
L1 STRUCTURE UPLOADED
L2 6 S L1
L3 62 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:25:21 ON 29 MAY 2007
L4 93 S L3
L5 73 S L4 AND DIABETES
L6 4 S L5 AND OBESITY AND HIGH BLOOD PRESSURE

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.95	219.31